ROCKVILLE, MARYLAND, UNITED STATES — February 17, 2026 NovaBridge announced dosing of the first patient in its global, randomized Phase 2 clinical trial evaluating Givastomig in combination with immunochemotherapy for first-line metastatic gastric cancer, marking a significant clinical development milestone. The study is designed to assess the safety and efficacy of the CLDN18.2 x 4-1BB bispecific antibody alongside standard-of-care nivolumab and chemotherapy regimens. Initiation of patient dosing signals transition of the investigational therapy into mid-stage clinical validation, building on encouraging early-phase data.
Science Significance
Givastomig represents an advanced bispecific antibody engineered to simultaneously target Claudin 18.2 (CLDN18.2) on tumor cells and activate T cells through the 4-1BB co-stimulatory pathway. This dual-targeting mechanism is designed to enhance immune-mediated tumor destruction while minimizing systemic toxicity. Phase 1b data demonstrated robust anti-tumor activity, including high objective response rates and durable progression-free survival in HER2-negative metastatic gastric cancer. The therapy’s tumor microenvironment-specific activation strategy highlights the next wave of precision immuno-oncology innovation aimed at improving response depth and durability.
Regulatory Significance
Advancement into a global Phase 2 randomized trial reflects regulatory alignment on the therapy’s clinical development pathway. Mid-stage trials are critical for dose optimization, comparative efficacy evaluation, and safety validation prior to potential registrational studies. The trial will enroll patients across international sites, generating data aligned with global regulatory expectations for biologics approval. Progression through Phase 2 represents a key inflection point toward future Biologics License Application submissions and commercialization pathways.
Business Significance
Advertisement
From a market perspective, metastatic gastric cancer represents a substantial commercial opportunity, with projections estimating multibillion-dollar therapeutic demand by 2030. Positive early data position givastomig as a potential best-in-class therapy within the CLDN18.2 targeting space. The Phase 2 program strengthens NovaBridge’s clinical pipeline value while supporting its transition into a mid-stage oncology biotechnology company. Strategic global partnerships and combination therapy frameworks further enhance development scalability and market positioning.
Patients’ Significance
Metastatic gastric cancer remains a high-mortality malignancy with limited durable first-line treatment options. Despite advances in checkpoint inhibitors and chemotherapy, many patients experience relapse or progression. Combination immunochemotherapy approaches incorporating novel bispecific antibodies may significantly improve response rates and survival outcomes. By targeting tumor antigens while simultaneously activating immune effector cells, givastomig offers a precision-guided therapeutic strategy designed to improve both efficacy and tolerability for patients facing advanced disease.
Policy Significance
Global oncology development programs align with healthcare policy priorities focused on expanding access to innovative biologics and improving survival in high-burden cancers. International clinical trial collaboration supports regulatory harmonization, accelerates drug development timelines, and enhances data generalizability across populations. As immuno-oncology therapies reshape cancer care standards, policy frameworks increasingly support expedited development, biomarker-driven trials, and combination regimens targeting unmet clinical needs.
The initiation of dosing in NovaBridge’s Phase 2 givastomig study marks a critical step forward in the evolution of targeted immunochemotherapy for metastatic gastric cancer. By integrating bispecific antibody innovation with established immunotherapy backbones, the trial seeks to redefine first-line treatment paradigms. As clinical data mature, givastomig may emerge as a transformative addition to the precision oncology arsenal, offering renewed hope for patients confronting advanced gastrointestinal malignancies.
Source: NovaBridge Biosciences press release
